New 1,4-Dihydropyridines Conjugated to Furoxanyl Moieties, Endowed with Both Nitric Oxide-like and Calcium Channel Antagonist Vasodilator Activities
A series of 4-phenyl-1,4-dihydropyridines substituted at the ortho and meta positions of the phenyl ring with NO-donating furoxan moieties and their non-NO-releasing furazan analogues were synthesized and pharmacologically characterized. The vasodilator activities of these compounds were evaluated o...
Saved in:
Published in | Journal of medicinal chemistry Vol. 41; no. 27; pp. 5393 - 5401 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
WASHINGTON
American Chemical Society
31.12.1998
Amer Chemical Soc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A series of 4-phenyl-1,4-dihydropyridines substituted at the ortho and meta positions of the phenyl ring with NO-donating furoxan moieties and their non-NO-releasing furazan analogues were synthesized and pharmacologically characterized. The vasodilator activities of these compounds were evaluated on rat aorta and expressed as EC50 values or as EC50 iGC values when obtained in the presence of inhibitors of guanylate cyclase methylene blue (MB) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). Affinities to 1,4-DHP receptors on Ca2+ channels, expressed as IC50 values, were determined through displacement experiments of [3H]nitrendipine on rat cortex homogenates. A linear correlation between IC50 and EC50 values was found for compounds unable to release NO. EC50 calcd values for derivatives containing NO-donor moieties, expression of the Ca2+-blocking component of their vasodilator activity, were interpolated on this linear regression. They showed a good correspondence with EC50 iGC values determined in the presence of soluble guanylate cyclase inhibitors. Analysis of EC50 iGC/EC50 ratios provided a useful tool to distinguish well-balanced hybrids from derivatives biased toward Ca2+-blocking or NO-dependent vasodilator activity. A detrimental effect on affinity to the 1,4-DHP receptor, due to substitution at the ortho and meta positions of the 4-phenyl ring, was observed. SAR to explain this effect is proposed. |
---|---|
AbstractList | A series of 4-phenyl-1,4-dihydropyridines substituted at the ortho and meta positions of the phenyl ring with NO-donating furoxan moieties and their non-NO-releasing furazan analogues were synthesized and pharmacologically characterized. The vasodilator activities of these compounds were evaluated on rat aorta and expressed as EC50 values or as EC50 iGC values when obtained in the presence of inhibitors of guanylate cyclase methylene blue (MB) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). Affinities to 1,4-DHP receptors on Ca2+ channels, expressed as IC50 values, were determined through displacement experiments of [3H]nitrendipine on rat cortex homogenates. A linear correlation between IC50 and EC50 values was found for compounds unable to release NO. EC50 calcd values for derivatives containing NO-donor moieties, expression of the Ca2+-blocking component of their vasodilator activity, were interpolated on this linear regression. They showed a good correspondence with EC50 iGC values determined in the presence of soluble guanylate cyclase inhibitors. Analysis of EC50 iGC/EC50 ratios provided a useful tool to distinguish well-balanced hybrids from derivatives biased toward Ca2+-blocking or NO-dependent vasodilator activity. A detrimental effect on affinity to the 1,4-DHP receptor, due to substitution at the ortho and meta positions of the 4-phenyl ring, was observed. SAR to explain this effect is proposed. A series of 4-phenyl-1,4-dihydropyridines substituted at the ortho and meta positions of the phenyl ring with NO-donating furoxan moieties and their non-NO-releasing furazan analogues were synthesized and pharmacologically characterized. The vasodilator activities of these compounds were evaluated on rat aorta and expressed as EC sub(50) values or as EC sub(50) super(iGC) values when obtained in the presence of inhibitors of guanylate cyclase methylene blue (MB) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). Affinities to 1,4-DHP receptors on Ca super(2+) channels, expressed as IC sub(50) values, were determined through displacement experiments of [ super(3)H]-nitrendipine on rat cortex homogenates. A linear correlation between IC sub(50) and EC sub(50) values was found for compounds unable to release NO. EC sub(50) super(calcd) values for derivatives containing NO-donor moieties, expression of the Ca super(2+)-blocking component of their vasodilator activity, were interpolated on this linear regression. They showed a good correspondence with EC sub(50) super(iGC) values determined in the presence of soluble guanylate cyclase inhibitors. Analysis of EC sub(50) super(iGC)/EC sub(50) ratios provided a useful tool to distinguish well-balanced hybrids from derivatives biased toward Ca super(2+)-blocking or NO-dependent vasodilator activity. A detrimental effect on affinity to the 1,4-DHP receptor, due to substitution at the ortho and meta positions of the 4-phenyl ring, was observed. SAR to explain this effect is proposed. A series of 4-phenyl-1,4-dihydropyridines substituted at the ortho and meta positions of the phenyl ring with NO-donating furoxan moieties and their non-NO-releasing furazan analogues were synthesized and pharmacologically characterized. The vasodilator activities of these compounds were evaluated on rat aorta and expressed as EC50 values or as EC50iGC values when obtained in the presence of inhibitors of guanylate cyclase methylene blue (MB) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). Affinities to 1, 4-DHP receptors on Ca2+ channels, expressed as IC50 values, were determined through displacement experiments of [3H]nitrendipine on rat cortex homogenates. A linear correlation between IC50 and EC50 values was found for compounds unable to release NO. EC50calcd values for derivatives containing NO-donor moieties, expression of the Ca2+-blocking component of their vasodilator activity, were interpolated on this linear regression. They showed a good correspondence with EC50iGC values determined in the presence of soluble guanylate cyclase inhibitors. Analysis of EC50iGC/EC50 ratios provided a useful tool to distinguish well-balanced hybrids from derivatives biased toward Ca2+-blocking or NO-dependent vasodilator activity. A detrimental effect on affinity to the 1, 4-DHP receptor, due to substitution at the ortho and meta positions of the 4-phenyl ring, was observed. SAR to explain this effect is proposed. A series of 4-phenyl-1,4-dihydropyridines substituted at the ortho and meta positions of the phenyl ring with NO-donating furoxan moieties and their non-NO-releasing furazan analogues were synthesized and pharmacologically characterized. The vasodilator activities of these compounds were evaluated on rat aorta and expressed as EC50 values or as EC50iGC values when obtained in the presence of inhibitors of guanylate cyclase methylene blue (MB) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-(ODQ). Affinities to 1,4-DHP receptors on Ca2+ channels, expressed as IC50 values, were determined through displacement experiments of [H-3]-nitrendipine on rat cortex homogenates. A linear correlation between IC50 and EC50 values was found for compounds unable to release NO. EC50calcd values for derivatives containing NO-donor moieties, expression of the Ca2+-blocking component of their vasodilator activity, were interpolated on this linear regression. They showed a good correspondence with EC50iGC values determined in the presence of soluble guanylate cyclase inhibitors. Analysis of (EC50EC50)-E-iGC/ ratios provided a useful tool to distinguish well-balanced hybrids from derivatives biased toward Ca2+-blocking or NO-dependent vasodilator activity. A detrimental effect on affinity to the 1,4-DHP receptor, due to substitution at the ortho and meta positions of the 4-phenyl ring, was observed. SAR to explain this effect is proposed. |
Author | Cena, Clara Gasco, Alberto Gasco, Andrea Marcello Visentin, Sonja Ermondi, Giuseppe Di Stilo, Antonella |
Author_xml | – sequence: 1 givenname: Antonella surname: Di Stilo fullname: Di Stilo, Antonella – sequence: 2 givenname: Sonja surname: Visentin fullname: Visentin, Sonja – sequence: 3 givenname: Clara surname: Cena fullname: Cena, Clara – sequence: 4 givenname: Andrea Marcello surname: Gasco fullname: Gasco, Andrea Marcello – sequence: 5 givenname: Giuseppe surname: Ermondi fullname: Ermondi, Giuseppe – sequence: 6 givenname: Alberto surname: Gasco fullname: Gasco, Alberto |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1658211$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9876109$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU9v0zAchiM0NLrBgQ-A5AMgTSxgO47_HEu2bqCxIW1w4BI5jrO6S-1iO2v7PfjAuGpVLkhwsS29z--17OcoO7DO6ix7ieB7BDH6MJsLDgtM2ZNshEoMc8IhOchGEGKcY4qLZ9lRCDMIYYFwcZgdCs4ogmKU_brWS4BOSX5mpuvWu8Xam9ZYHUDl7Gy4l1G3IDowGbxbSbvuwRdndDQ6nIJz27plipcmTsFHl5ZrE71R4GZlWp335kEDaVtQyV6ZYQ6qqbRW92Bso7x31oQIvsvgWtPL6DwYq2gezab6efa0k33QL3b7cfZtcn5XXeZXNxefqvFVLgnkMSe6Iw1EhWx4w6RqSiJKpjqmW8EarlGnBG8QL5VqFaKdIJIyTCErOBOMCFYcZ2-3vQvvfg46xHpugtJ9L612Q6ipQIgxSv8JIkagwAIl8GQLKu9C8LqrF97MpV_XCNYbVfVeVWJf7UqHZq7bPblzk_LXu1wGJfvOS6tM-FNIS47R5kq-xZa6cV1QRlul91RSDhkTmGwOkFYmymicrdxgYxp99_-jic63dBKnV3tM-oc6vYaV9d3X2_ribIJ-3H6-rMvEv9nyUoV65gZvk8u__MNv8OvZow |
CODEN | JMCMAR |
CitedBy_id | crossref_primary_10_1007_s00706_012_0742_4 crossref_primary_10_1039_D1OB00145K crossref_primary_10_1246_bcsj_79_454 crossref_primary_10_1016_j_catcom_2007_03_004 crossref_primary_10_1038_sj_bjp_0707224 crossref_primary_10_1080_00397910902987792 crossref_primary_10_1016_j_arabjc_2011_01_027 crossref_primary_10_1080_00304940509354882 crossref_primary_10_1002_jccs_202000303 crossref_primary_10_1002_chir_22083 crossref_primary_10_1007_s00044_015_1417_6 crossref_primary_10_1016_j_tetlet_2015_01_163 crossref_primary_10_1080_00397910701357007 crossref_primary_10_1016_j_ejmech_2017_12_047 crossref_primary_10_1016_S0960_894X_99_00445_X crossref_primary_10_1088_1757_899X_763_1_012016 crossref_primary_10_1016_j_bmc_2010_02_058 crossref_primary_10_1007_s11172_017_1734_7 crossref_primary_10_1021_jm031109v crossref_primary_10_3390_molecules17055339 crossref_primary_10_1021_jm0108799 crossref_primary_10_1039_b902112d crossref_primary_10_1080_07370652_2017_1302519 crossref_primary_10_1021_jo702548b crossref_primary_10_1021_jm049681p crossref_primary_10_1016_j_tetlet_2009_07_018 crossref_primary_10_1002_ddr_10284 crossref_primary_10_1016_j_tetlet_2005_05_148 crossref_primary_10_1021_jm0600186 crossref_primary_10_1002_chir_22135 crossref_primary_10_1016_j_bbapap_2004_09_027 crossref_primary_10_1002_cmdc_200600248 crossref_primary_10_1071_CH08414 crossref_primary_10_3389_fphar_2019_01648 crossref_primary_10_1007_s11172_008_0349_4 crossref_primary_10_1016_j_tet_2015_06_085 crossref_primary_10_1158_1535_7163_MCT_07_2037 crossref_primary_10_1002_aoc_5026 crossref_primary_10_3390_ijms21218099 crossref_primary_10_1016_j_tet_2006_05_037 crossref_primary_10_1080_10406638_2020_1869795 crossref_primary_10_1007_s00706_015_1557_x crossref_primary_10_1002_cmdc_201000198 crossref_primary_10_1021_acsmacrolett_3c00298 crossref_primary_10_1021_jm0704595 crossref_primary_10_2174_1570178620666230905145050 crossref_primary_10_1016_j_phrs_2013_09_008 crossref_primary_10_1016_j_rechem_2024_101407 crossref_primary_10_1016_j_farmac_2003_12_008 crossref_primary_10_3389_fphar_2020_569489 crossref_primary_10_1016_j_bmc_2011_08_018 crossref_primary_10_1021_cr000040l crossref_primary_10_1016_j_bmc_2008_03_014 crossref_primary_10_1016_j_jece_2022_108854 crossref_primary_10_1021_op700187w crossref_primary_10_1021_acs_jmedchem_7b01332 crossref_primary_10_1021_acs_joc_8b01875 crossref_primary_10_1016_j_arabjc_2012_10_017 crossref_primary_10_1016_j_bmc_2014_06_016 crossref_primary_10_1016_S0968_0896_00_00098_5 crossref_primary_10_1016_j_bioorg_2021_104911 crossref_primary_10_1124_dmd_104_002089 crossref_primary_10_1016_j_tetlet_2017_02_038 crossref_primary_10_2174_1385272823666190802092406 crossref_primary_10_1007_s11164_015_2163_6 crossref_primary_10_1016_j_athoracsur_2013_05_020 crossref_primary_10_1080_10406638_2021_1991398 crossref_primary_10_1111_cbdd_14276 crossref_primary_10_1002_cjoc_200790198 crossref_primary_10_1021_jm010394k crossref_primary_10_1016_j_ejmech_2014_07_007 crossref_primary_10_1080_14756366_2016_1187605 crossref_primary_10_1002_aoc_4357 crossref_primary_10_1016_j_tetlet_2016_07_071 crossref_primary_10_1002_jhet_5570430531 crossref_primary_10_1039_D3GC01229H crossref_primary_10_1016_j_cdc_2021_100688 crossref_primary_10_1016_j_bmc_2015_05_050 crossref_primary_10_1016_j_athoracsur_2015_10_029 crossref_primary_10_1021_jm020969t crossref_primary_10_1021_jm0510530 |
Cites_doi | 10.1021/jm00051a020 10.1002/jhet.5570260523 10.1007/BF00169084 10.1016/0006-2952(92)90379-W 10.1023/A:1012136030849 10.1002/med.2610090203 10.1248/cpb.27.1426 10.1021/jm00025a012 10.1021/jm00119a009 10.1021/jm00022a001 10.1002/ardp.19973300804 10.1021/jm960379t 10.1007/BF01431809 10.1111/j.1476-5381.1995.tb14946.x |
ContentType | Journal Article |
Copyright | Copyright © 1998 American Chemical Society 1999 INIST-CNRS |
Copyright_xml | – notice: Copyright © 1998 American Chemical Society – notice: 1999 INIST-CNRS |
DBID | BSCLL 1KM BLEPL DTL FFIDB IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7X8 |
DOI | 10.1021/jm9803267 |
DatabaseName | Istex Index Chemicus Web of Science Core Collection Science Citation Index Expanded Web of Science - Science Citation Index Expanded - 1998 Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitle | Web of Science MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | Calcium & Calcified Tissue Abstracts MEDLINE - Academic MEDLINE Web of Science |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 1KM name: Index Chemicus url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC sourceTypes: Enrichment Source Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-4804 |
EndPage | 5401 |
ExternalDocumentID | 10_1021_jm9803267 9876109 1658211 000077924000006 ark_67375_TPS_GDF1ZSJH_5 a30913110 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - .K2 3EH 53G 55 55A 5GY 5RE 5VS 7~N 9M8 AABXI ABFLS ABMVS ABOCM ABPTK ABUCX ACGFS ACJ ACS ADKFC AEESW AENEX AFEFF AFFNX AJYGW ALMA_UNASSIGNED_HOLDINGS ANTXH AQSVZ BAANH CS3 DU5 EBS ED ED~ EJD F5P GJ GNL IH9 IHE JG JG~ K2 L7B LG6 MVM NHB P2P ROL TN5 UI2 VF5 VG9 W1F WH7 X X7M XFK YZZ ZE2 ZGI ZY4 --- -~X .55 .GJ AAHBH ABJNI ABQRX ABTAH ACGFO ADHLV AGXLV AHGAQ BSCLL CUPRZ GGK IH2 XSW YQT 1KM BLEPL DTL GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED .HR 1KJ 1WB 3O- 4.4 6P2 6TJ AAYOK ABFRP ABHMW IQODW OHT RNS UBC CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7X8 |
ID | FETCH-LOGICAL-a408t-4ef4b013ab8b7acb54957cf7ed97b8e1fc98b185ccdc16f94a672607387974973 |
IEDL.DBID | ACS |
ISICitedReferencesCount | 109 |
ISICitedReferencesURI | https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000077924000006 |
ISSN | 0022-2623 |
IngestDate | Fri Aug 16 07:29:54 EDT 2024 Fri Aug 16 00:10:16 EDT 2024 Fri Aug 23 02:29:33 EDT 2024 Sat Sep 28 07:32:29 EDT 2024 Sun Jul 28 03:31:50 EDT 2024 Fri Nov 08 20:01:26 EST 2024 Wed Sep 18 07:20:47 EDT 2024 Wed Oct 30 09:46:20 EDT 2024 Thu Aug 27 13:42:12 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 27 |
Keywords | UNSYMMETRICALLY SUBSTITUTED FUROXANS DONORS Vasodilator agent Rat Nitrogen heterocycle Nitrone Rodentia Central nervous system Calcium antagonist Smooth muscle In vitro Vertebrata Mammalia Structure activity relation Nitric oxide Blood vessel Diester Aorta Dihydropyridine derivatives Chemical synthesis Brain (vertebrata) Oxygen nitrogen heterocycle |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
LogoURL | https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg |
MergedId | FETCHMERGED-LOGICAL-a408t-4ef4b013ab8b7acb54957cf7ed97b8e1fc98b185ccdc16f94a672607387974973 |
Notes | ark:/67375/TPS-GDF1ZSJH-5 istex:811A599D922D08C0FBAE8A037CD5AA82020E6C93 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ORCID | 0000-0003-3710-3102 |
PMID | 9876109 |
PQID | 17409291 |
PQPubID | 23462 |
PageCount | 9 |
ParticipantIDs | pubmed_primary_9876109 crossref_primary_10_1021_jm9803267 webofscience_primary_000077924000006CitationCount pascalfrancis_primary_1658211 istex_primary_ark_67375_TPS_GDF1ZSJH_5 webofscience_primary_000077924000006 acs_journals_10_1021_jm9803267 proquest_miscellaneous_17409291 proquest_miscellaneous_69117766 |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N ACJ VG9 W1F ANTXH ACS AEESW AFEFF .K2 ABMVS ABUCX IH9 BAANH AQSVZ ED~ UI2 |
PublicationCentury | 1900 |
PublicationDate | 1998-12-31 |
PublicationDateYYYYMMDD | 1998-12-31 |
PublicationDate_xml | – month: 12 year: 1998 text: 1998-12-31 day: 31 |
PublicationDecade | 1990 |
PublicationPlace | WASHINGTON |
PublicationPlace_xml | – name: WASHINGTON – name: Washington, DC – name: United States |
PublicationTitle | Journal of medicinal chemistry |
PublicationTitleAbbrev | J MED CHEM |
PublicationTitleAlternate | J. Med. Chem |
PublicationYear | 1998 |
Publisher | American Chemical Society Amer Chemical Soc |
Publisher_xml | – name: American Chemical Society – name: Amer Chemical Soc |
References | TRIGGLE, DJ (WOS:A1989T870400002) 1989; 9 HECKER, M (WOS:A1995QR44700013) 1995; 351 Hu, H (WOS:A1997YD71300014) 1997; 81 GASCO, A (WOS:A1972M803400019) 1972; 9 Sorba, G (WOS:A1997XH83500023) 1997; 40 GASCO, AM (WOS:A1995RG03800021) 1995; 32 HANSCH C (WOS:000077924000006.16) 1995 MEDANA, C (WOS:A1994PW56600020) 1994; 37 Gasco, A (WOS:A1996VW09400001) 1996; 51 Christiaans, JAM (WOS:A1996TQ08900001) 1996; 4 FRUTTERO, R (WOS:A1989AW86900024) 1989; 26 FEELISCH, M (WOS:A1992JR49900020) 1992; 44 Fruttero, R (WOS:000077722900005) 1998 FRUTTERO R (WOS:000077924000006.12) 1998 CHRISTIAANS, JAM (WOS:A1993MJ95800003) 1993; 28 COBURN, RA (WOS:A1988Q721200009) 1988; 31 Blinnikov, AN (WOS:A1996WF53700029) 1996; 45 HARDMAN JG (WOS:000077924000006.17) 1996 BOHN, H (WOS:A1995QU93600013) 1995; 114 IWANAMI, M (WOS:A1979HD24200019) 1979; 27 FRUTTERO, R (WOS:A1995TJ64600012) 1995; 38 KERWIN, JF (WOS:A1995TD46600001) 1995; 38 Boschi, D (WOS:000071391800016) 1997; 14 Lehmann, J (WOS:A1997YC22900003) 1997; 330 (WOS:000077924000006.1) 1992 jm9803267b00007/jm9803267b00007_1 Log (jm9803267b00020/jm9803267b00020_1) Sorba G. (jm9803267b00009/jm9803267b00009_1) 1997; 40 Medana C. (jm9803267b00015/jm9803267b00015_1) 1994; 37 Triggle D. J. (jm9803267b00001/jm9803267b00001_1) 1989; 9 Feelisch M. (jm9803267b00008/jm9803267b00008_1) 1992; 44 Christiaans J. A. M. (jm9803267b00005/jm9803267b00005_1) 1996; 4 jm9803267b00018/jm9803267b00018_1 Coburn R. A. (jm9803267b00016/jm9803267b00016_1) 1988; 31 Fruttero R. (jm9803267b00017/jm9803267b00017_1) 1998; 495 Gasco A. (jm9803267b00024/jm9803267b00024_1) 1972; 9 Hu H. (jm9803267b00014/jm9803267b00014_1) 1997; 81 Iwanami M. (jm9803267b00023/jm9803267b00023_1) 1979; 27 Kerwin J. F. (jm9803267b00003/jm9803267b00003_1) 1995; 38 Fruttero R. (jm9803267b00021/jm9803267b00021_1) 1989; 26 Christiaans J. A. M. (jm9803267b00026/jm9803267b00026_1) 1993; 28 Blinnikov A. N. (jm9803267b00025/jm9803267b00025_1) 1996; 45 Bohn H. (jm9803267b00010/jm9803267b00010_1) 1995; 114 Gasco A. (jm9803267b00004/jm9803267b00004_1) 1996; 51 (jm9803267b00002/jm9803267b00002_1) 1996 Fruttero R. (jm9803267b00012/jm9803267b00012_1) 1995; 38 Lehmann J. (jm9803267b00006/jm9803267b00006_1) 1997; 330 Gasco A. M. (jm9803267b00022/jm9803267b00022_1) 1995; 32 Boschi D. (jm9803267b00013/jm9803267b00013_1) 1997; 14 Hecker M. (jm9803267b00011/jm9803267b00011_1) 1995; 351 |
References_xml | – year: 1992 ident: WOS:000077924000006.1 – volume: 27 start-page: 1426 year: 1979 ident: WOS:A1979HD24200019 article-title: SYNTHESIS OF NEW WATER-SOLUBLE DIHYDROPYRIDINE VASODILATORS publication-title: CHEMICAL & PHARMACEUTICAL BULLETIN contributor: fullname: IWANAMI, M – volume: 32 start-page: 811 year: 1995 ident: WOS:A1995RG03800021 article-title: UNSYMMETRICALLY SUBSTITUTED FUROXANS .15. BROMINATION OF DIMETHYLFUROXAN AND RELATED-COMPOUNDS WITH NBS publication-title: JOURNAL OF HETEROCYCLIC CHEMISTRY contributor: fullname: GASCO, AM – start-page: 495 year: 1998 ident: WOS:000077722900005 article-title: Electronic substituent effects of furoxan and furazan systems publication-title: JOURNAL OF CHEMICAL RESEARCH-S contributor: fullname: Fruttero, R – volume: 31 start-page: 2103 year: 1988 ident: WOS:A1988Q721200009 article-title: 1,4-DIHYDROPYRIDINE ANTAGONIST ACTIVITIES AT THE CALCIUM-CHANNEL - A QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP APPROACH publication-title: JOURNAL OF MEDICINAL CHEMISTRY contributor: fullname: COBURN, RA – volume: 26 start-page: 1345 year: 1989 ident: WOS:A1989AW86900024 article-title: UNSYMMETRICALLY SUBSTITUTED FUROXANS .11. METHYLFUROXANCARBALDEHYDES publication-title: JOURNAL OF HETEROCYCLIC CHEMISTRY contributor: fullname: FRUTTERO, R – volume: 81 start-page: 742 year: 1997 ident: WOS:A1997YD71300014 article-title: Direct inhibition of expressed cardiac L-type Ca2+ channels by S-nitrosothiol nitric oxide donors publication-title: CIRCULATION RESEARCH contributor: fullname: Hu, H – volume: 114 start-page: 1605 year: 1995 ident: WOS:A1995QU93600013 article-title: CARDIOVASCULAR ACTIONS OF THE FUROXAN CAS-1609, A NOVEL NITRIC-OXIDE DONOR publication-title: BRITISH JOURNAL OF PHARMACOLOGY contributor: fullname: BOHN, H – volume: 45 start-page: 1692 year: 1996 ident: WOS:A1996WF53700029 article-title: alpha-hydroxyalkyl(benzyl)furazans and alpha-hydroxyalkyl(benzyl)furoxans - Synthesis and reactivity publication-title: RUSSIAN CHEMICAL BULLETIN contributor: fullname: Blinnikov, AN – year: 1996 ident: WOS:000077924000006.17 publication-title: PHARM BASIS THERAPEU contributor: fullname: HARDMAN JG – volume: 40 start-page: 2288 year: 1997 ident: WOS:A1997XH83500023 article-title: Water soluble furoxan derivatives as NO prodrugs (vol 40, pg 467, 1997) publication-title: JOURNAL OF MEDICINAL CHEMISTRY contributor: fullname: Sorba, G – volume: 37 start-page: 4412 year: 1994 ident: WOS:A1994PW56600020 article-title: FUROXANS AS NITRIC-OXIDE DONORS - 4-PHENYL-3-FUROXANCARBONITRILE - THIOL-MEDIATED NITRIC-OXIDE RELEASE AND BIOLOGICAL EVALUATION publication-title: JOURNAL OF MEDICINAL CHEMISTRY contributor: fullname: MEDANA, C – volume: 51 start-page: 617 year: 1996 ident: WOS:A1996VW09400001 article-title: NO-donors: An emerging class of compounds in medicinal chemistry publication-title: FARMACO contributor: fullname: Gasco, A – volume: 38 start-page: 4343 year: 1995 ident: WOS:A1995TD46600001 article-title: NITRIC-OXIDE - A NEW PARADIGM FOR 2ND-MESSENGERS publication-title: JOURNAL OF MEDICINAL CHEMISTRY contributor: fullname: KERWIN, JF – volume: 9 start-page: 577 year: 1972 ident: WOS:A1972M803400019 article-title: SYNTHESIS AND STRUCTURE OF SOME ASYMMETRICALLY SUBSTITUTED FUROXANS .1. publication-title: JOURNAL OF HETEROCYCLIC CHEMISTRY contributor: fullname: GASCO, A – volume: 44 start-page: 1149 year: 1992 ident: WOS:A1992JR49900020 article-title: THIOL-MEDIATED GENERATION OF NITRIC-OXIDE ACCOUNTS FOR THE VASODILATOR ACTION OF FUROXANS publication-title: BIOCHEMICAL PHARMACOLOGY contributor: fullname: FEELISCH, M – year: 1995 ident: WOS:000077924000006.16 publication-title: EXPLORING QSAR contributor: fullname: HANSCH C – start-page: 2545 year: 1998 ident: WOS:000077924000006.12 publication-title: J CHEM RES M contributor: fullname: FRUTTERO R – volume: 351 start-page: 426 year: 1995 ident: WOS:A1995QR44700013 article-title: CHARACTERIZATION OF FUROXANS AS A NEW CLASS OF TOLERANCE-RESISTANT NITROVASODILATORS publication-title: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY contributor: fullname: HECKER, M – volume: 330 start-page: 247 year: 1997 ident: WOS:A1997YC22900003 article-title: Organic nitrates .2. Synthesis and biological activities of 4-nitrooxymethylphenyl-1,4-dihydropyridines publication-title: ARCHIV DER PHARMAZIE contributor: fullname: Lehmann, J – volume: 4 start-page: 1 year: 1996 ident: WOS:A1996TQ08900001 article-title: Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule publication-title: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES contributor: fullname: Christiaans, JAM – volume: 9 start-page: 123 year: 1989 ident: WOS:A1989T870400002 article-title: CA-2+ CHANNEL LIGANDS - STRUCTURE-FUNCTION-RELATIONSHIPS OF THE 1,4-DIHYDROPYRIDINES publication-title: MEDICINAL RESEARCH REVIEWS contributor: fullname: TRIGGLE, DJ – volume: 28 start-page: 859 year: 1993 ident: WOS:A1993MJ95800003 article-title: SYNTHESIS AND IN-VITRO PHARMACOLOGY OF NEW 1,4-DIHYDROPYRIDINES .1. 2-(OMEGA-AMINOALKYLTHIOMETHYL)-1,4-DIHYDROPYRIDINES AS POTENT CALCIUM-CHANNEL BLOCKERS publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY contributor: fullname: CHRISTIAANS, JAM – volume: 38 start-page: 4944 year: 1995 ident: WOS:A1995TJ64600012 article-title: THE FUROXAN SYSTEM AS A USEFUL TOOL FOR BALANCING HYBRIDS WITH MIXED ALPHA(1)-ANTAGONIST AND NO-LIKE VASODILATOR ACTIVITIES publication-title: JOURNAL OF MEDICINAL CHEMISTRY contributor: fullname: FRUTTERO, R – volume: 14 start-page: 1750 year: 1997 ident: WOS:000071391800016 article-title: Studies on agents with mixed NO-dependent vasodilating and beta-blocking activities publication-title: PHARMACEUTICAL RESEARCH contributor: fullname: Boschi, D – volume: 37 start-page: 4416 year: 1994 ident: jm9803267b00015/jm9803267b00015_1 publication-title: J. Med. Chem. doi: 10.1021/jm00051a020 contributor: fullname: Medana C. – volume: 26 start-page: 1347 year: 1989 ident: jm9803267b00021/jm9803267b00021_1 publication-title: J. Heterocycl. Chem. doi: 10.1002/jhet.5570260523 contributor: fullname: Fruttero R. – volume: 9 start-page: 580 year: 1972 ident: jm9803267b00024/jm9803267b00024_1 publication-title: J. Heterocycl. Chem. contributor: fullname: Gasco A. – volume: 51 start-page: 635 year: 1996 ident: jm9803267b00004/jm9803267b00004_1 publication-title: Farmaco contributor: fullname: Gasco A. – volume: 81 start-page: 752 year: 1997 ident: jm9803267b00014/jm9803267b00014_1 publication-title: Circ. Res. contributor: fullname: Hu H. – ident: jm9803267b00007/jm9803267b00007_1 – volume: 351 start-page: 432 year: 1995 ident: jm9803267b00011/jm9803267b00011_1 publication-title: Naunyn-Schmiedeberg's Arch. Pharmacol. doi: 10.1007/BF00169084 contributor: fullname: Hecker M. – volume: 44 start-page: 1157 year: 1992 ident: jm9803267b00008/jm9803267b00008_1 publication-title: Biochem. Pharmacol. doi: 10.1016/0006-2952(92)90379-W contributor: fullname: Feelisch M. – volume: 14 start-page: 1758 year: 1997 ident: jm9803267b00013/jm9803267b00013_1 publication-title: Pharm. Res. doi: 10.1023/A:1012136030849 contributor: fullname: Boschi D. – volume-title: v.1.0 ident: jm9803267b00020/jm9803267b00020_1 contributor: fullname: Log – ident: jm9803267b00018/jm9803267b00018_1 – volume: 9 start-page: 180 year: 1989 ident: jm9803267b00001/jm9803267b00001_1 publication-title: Med. Res. Rev. doi: 10.1002/med.2610090203 contributor: fullname: Triggle D. J. – volume: 27 start-page: 1440 year: 1979 ident: jm9803267b00023/jm9803267b00023_1 publication-title: Chem. Pharm. Bull. doi: 10.1248/cpb.27.1426 contributor: fullname: Iwanami M. – volume-title: The Pharmacological Basis of Therapeutics year: 1996 ident: jm9803267b00002/jm9803267b00002_1 – volume: 38 start-page: 4949 year: 1995 ident: jm9803267b00012/jm9803267b00012_1 publication-title: J. Med. Chem. doi: 10.1021/jm00025a012 contributor: fullname: Fruttero R. – volume: 28 start-page: 867 year: 1993 ident: jm9803267b00026/jm9803267b00026_1 publication-title: Eur. J. Med. Chem. contributor: fullname: Christiaans J. A. M. – volume: 31 start-page: 2107 year: 1988 ident: jm9803267b00016/jm9803267b00016_1 publication-title: J. Med. Chem. doi: 10.1021/jm00119a009 contributor: fullname: Coburn R. A. – volume: 495 start-page: 2563 year: 1998 ident: jm9803267b00017/jm9803267b00017_1 publication-title: J. Chem. Res. contributor: fullname: Fruttero R. – volume: 38 start-page: 4362 year: 1995 ident: jm9803267b00003/jm9803267b00003_1 publication-title: J. Med. Chem. doi: 10.1021/jm00022a001 contributor: fullname: Kerwin J. F. – volume: 330 start-page: 252 year: 1997 ident: jm9803267b00006/jm9803267b00006_1 publication-title: Arch. Pharm. doi: 10.1002/ardp.19973300804 contributor: fullname: Lehmann J. – volume: 4 start-page: 22 year: 1996 ident: jm9803267b00005/jm9803267b00005_1 publication-title: Eur. J. Pharmacol. Sci. contributor: fullname: Christiaans J. A. M. – volume: 40 start-page: 469 year: 1997 ident: jm9803267b00009/jm9803267b00009_1 publication-title: J. Med. Chem. doi: 10.1021/jm960379t contributor: fullname: Sorba G. – volume: 45 start-page: 1698 year: 1996 ident: jm9803267b00025/jm9803267b00025_1 publication-title: Russ. Chem. Bull. doi: 10.1007/BF01431809 contributor: fullname: Blinnikov A. N. – volume: 32 start-page: 813 year: 1995 ident: jm9803267b00022/jm9803267b00022_1 publication-title: J. Heterocycl. Chem. contributor: fullname: Gasco A. M. – volume: 114 start-page: 1612 year: 1995 ident: jm9803267b00010/jm9803267b00010_1 publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.1995.tb14946.x contributor: fullname: Bohn H. |
SSID | ssj0003123 |
Score | 1.9955451 |
Snippet | A series of 4-phenyl-1,4-dihydropyridines substituted at the ortho and meta positions of the phenyl ring with NO-donating furoxan moieties and their... |
Source | Web of Science |
SourceID | proquest crossref pubmed pascalfrancis webofscience istex acs |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5393 |
SubjectTerms | 4-Phenyl-1,4-dihydropyridines Animals Aorta, Thoracic - drug effects Aorta, Thoracic - physiology Binding, Competitive Biological and medical sciences Calcium Channel Blockers - chemical synthesis Calcium Channel Blockers - chemistry Calcium Channel Blockers - pharmacology Cardiovascular system Cerebral Cortex - metabolism Chemistry, Medicinal Dihydropyridines - chemical synthesis Dihydropyridines - chemistry Dihydropyridines - pharmacology Enzyme Inhibitors - pharmacology Guanylate Cyclase - antagonists & inhibitors In Vitro Techniques Life Sciences & Biomedicine Male Medical sciences Methylene Blue - pharmacology Miscellaneous Muscle Contraction - drug effects Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - physiology Nifedipine - pharmacology Nitric Oxide Donors - chemical synthesis Nitric Oxide Donors - chemistry Nitric Oxide Donors - pharmacology Oxadiazoles - chemical synthesis Oxadiazoles - chemistry Oxadiazoles - pharmacology Pharmacology & Pharmacy Pharmacology. Drug treatments Quinoxalines - pharmacology Radioligand Assay Rats Rats, Wistar Science & Technology Structure-Activity Relationship Vasodilator Agents - chemical synthesis Vasodilator Agents - chemistry Vasodilator Agents - pharmacology |
Title | New 1,4-Dihydropyridines Conjugated to Furoxanyl Moieties, Endowed with Both Nitric Oxide-like and Calcium Channel Antagonist Vasodilator Activities |
URI | http://dx.doi.org/10.1021/jm9803267 https://api.istex.fr/ark:/67375/TPS-GDF1ZSJH-5/fulltext.pdf http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000077924000006 https://www.ncbi.nlm.nih.gov/pubmed/9876109 https://search.proquest.com/docview/17409291 https://search.proquest.com/docview/69117766 |
Volume | 41 |
WOS | 000077924000006 |
WOSCitedRecordID | wos000077924000006 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfG9gAvfAwmAmxYMO2p2fLhxPHjSFeqSRuV2qGJl8iJHZG1S6Y2ESt_B38wd0nTbqIMXvKQOJbj_Oy78939jpB9K_FQDASm66TcZDZchI5T0xepl6RMxqyuGXl27vcv2Omld7lBPv7Fg-_YR1fXIrBAyeCPyJbDYVGg_hMOl9utaztuSwnugDBv6YPuvoqiJ5ndEz1bOIu3GAopZzAbaVPGYp2euVYk1eKn94x02ySeJupkfFiV8WHy809Ox4e-7Dl5ulA_6XGDlxdkQ-fb5HHYVn3bJgeDhst63qGjVWrWrEMP6GDFcj1_SX7B9kjtDjO72fe5mhY382mmMIaehkV-VeHpnKJlQXsVDBl2nAk9KzKN9K0depKr4gc8xkNg-gmwQs8zrBRAv9xmSpuTbKypzBUN5STJqmuKKRC5hmHn6ENDrl_6Vc4KlU3wyIAeJ3UJDOj6FbnonYzCvrko8WBKZgWlyXTK8CRWxkHMZRKDteohUZJWgseBttNEBDFgKUlUYvupYNLnYIFxN-BgCAnu7pDNvMj1a0JVwJirpLI8SzFQc2KV2o70XcZduB8rg-wBBqLFEp1FtffdAeun_QsG-dDCI7ppqD7WNTqogbNsIadjjI3jXjQaDKPP3Z79bXjajzyD7N5D1qpLH3OTbYO8b5EWwS9GN43MdVHBwDjY3I54oIUv0NXu-wbZaSC67FyAcLMtYZD9u5BdPq4d11xg3DDqKQax_6dZuGCLR5aE8s2_pvEteVLnbdZkmO_IZjmt9C4obmW8Vy_c37FiO8w |
link.rule.ids | 315,783,787,2772,27088,27936,27937,57070,57120 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgexgvfAwmAmyz0NSnZuTDiePHka2UsZZK69DES-TEjsjaJVOTiJW_gz-Ys9O0G6pgL31oXOtq_-K78939DqEDK_GUGghM10mpSWz4YDJOTZ-lXpISHhPdM3Iw9PsX5PTSu1zQ5KhaGBCihJlKHcRfsQvYH66uWWCBrUEfo02PAlCVGRSeL09d13bclhncAZ3esgjd_anSQEl5TwNtqsW8VRmRvIRFSZtuFuvMzbWaSWuh3rOmnZGWXyefTA7rKj5Mfv1F7fiwP_gcPV0Yo_ioQc8L9Ejm22grbHvAbaPOqGG2nnfxeFWoVXZxB49WnNfzl-g3HJbY7hLzOPsxF7PiZj7LhMqox2GRX9Xqrk7gqsC9GiSH82eKB0UmFZlrF5_kovgJj9WVMP4IyMHDTPUNwF9vMyHNaTaRmOcCh3yaZPU1VgURuQSxcxVRU8y_-BsvC5FN1QUCPkp0QwyY-hW66J2Mw765aPhgcmIFlUlkStS9LI-DmPIkBt_VU7RJUjAaB9JOExbEgKwkEYntp4xwn4I_Rt2AglvEqLuDNvIil68RFgEhruDC8ixBwOiJRWo73HcJdeH7WBhoDzYhWrywZaRj8Q74Qu0uGOh9i5LopiH-WDeoo_GzHMFnE5UpR71oPDqPPh337O_np_3IM9DuPYCtpvRVpbJtoP0WcBFssQra8FwWNQhGwQN32D9G-EwF3n3fQDsNUpeTM1B1tsUMdHAXucvHOoxNmcoiVlaLgeyHDAsX3PGKM6F6879l3Edb_fHgLDr7PPzyFj3RFZ2aJvMd2qhmtdwFk66K9_S7_AdWiUQs |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgk4AXPgYTAbZZaOpTM_LhxPFjSVfKYF2lbmjiJXLiRGTtkqpJxcrfwR_MXZq0G6pgL31oHMuxf_bd-e5-R8ihETkoBjzdthKuMxN-RBwmuisSJ0qYDFlVM_J04PYv2Mmlc1kbipgLA4MooKeicuLjrp6qpGYYMD9cXQvPAH2DPyTbDjctLNXQ8Uerk9c2LbthB7dArjdMQrdfRSkUFXek0DZO6A1GRcoCJiZZVrTYpHJulE6VJOo9I2erb6gCUMZH8zI8in79Re94_498Tp7WSintLFH0gjyIsx3y2G9qwe2Q1nDJcL1o0_N1wlbRpi06XHNfL16S33BoUrPN9G76Y6Fm-XQxSxVG1lM_z67meGenaJnT3hxGD-fQhJ7maYykrm16nKn8JzzGq2H6ERBEBynWD6BnN6mK9Uk6jqnMFPXlJErn1xQTI7IYhp2hZw0ZgOk3WeQqneBFAu1EVWEM6PoVuegdn_t9vS78oEtmeKXO4oTh_awMvZDLKAQb1kH6pFgJHnqxmUTCCwFhUaQi000Eky4Hu4zbHgfzSHB7l2xleRa_JlR5jNlKKsMxFAPlJ1SJaUnXZtyG_0OlkX1YiKDeuEVQ-eQtsImaVdDI-wYpwXRJALKpUavC0KqFnI0xYo47wflwFHzq9szvo5N-4Ghk7w7I1l26mLFsauSgAV0AS4zOG5nF-RwGxsESt8Q_WrgCHfCuq5HdJVpXnQsQeaYhNHJ4G72rx5U7mwuMJkbtRSPmfZr5NYc8cieUb_43jQfk0bDbC75-Hnx5S55UiZ0VW-Y7slXO5vEeaHZluF9t5z-SNkam |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+1%2C4-Dihydropyridines+Conjugated+to+Furoxanyl+Moieties%2C+Endowed+with+Both+Nitric+Oxide-like+and+Calcium+Channel+Antagonist+Vasodilator+Activities&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Di+Stilo%2C+A&rft.au=Visentin%2C+S&rft.au=Cena%2C+C&rft.au=Gasco%2C+A+M&rft.date=1998-12-31&rft.issn=0022-2623&rft.volume=41&rft.issue=27&rft.spage=5393&rft.epage=5401&rft_id=info:doi/10.1021%2Fjm9803267&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon |